A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Beckman Symposium Bookmark and Share

The 23rd Beckman Symposium - Antibody Engineering

Date
Friday, December 6, 2013
8:30 a.m. to 5 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 23rd Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2013 Speaker List:
 
Patrick A. Baeuerle, Ph.D.
Amgen Research, Munich, Germany
 
Shmuel Cabilly, Ph.D.
High Tech Investor and Board Member
 
Paul Carter, Ph.D.
Genentech
 
Herbert A. Heynecker, Ph.D.
Advisor, Thuja Capital
 
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
Arthur D. Riggs, Ph.D.
City of Hope
 
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
E. Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
Anna Wu, Ph.D.
University of California, Los Angeles

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

2013 Symposium Program

8:30 to 9 a.m.
Registration
 

9 to 9:10 a.m.
Welcome
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
 
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
 
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
 
10:10 to 10:30 a.m.
Break
 
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
 
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
 
12:10 to 1:10 p.m.
Lunch
 
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
 
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
3 to 3:20 p.m.
Break
 
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany

Registration

*Registration and lunches are limited to the first 350 registrants*
 

Beckman Symposium

The 23rd Beckman Symposium - Antibody Engineering

Date
Friday, December 6, 2013
8:30 a.m. to 5 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 23rd Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2013 Speaker List:
 
Patrick A. Baeuerle, Ph.D.
Amgen Research, Munich, Germany
 
Shmuel Cabilly, Ph.D.
High Tech Investor and Board Member
 
Paul Carter, Ph.D.
Genentech
 
Herbert A. Heynecker, Ph.D.
Advisor, Thuja Capital
 
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
Arthur D. Riggs, Ph.D.
City of Hope
 
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
E. Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
Anna Wu, Ph.D.
University of California, Los Angeles

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

Symposium Program

2013 Symposium Program

8:30 to 9 a.m.
Registration
 

9 to 9:10 a.m.
Welcome
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
 
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
 
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
 
10:10 to 10:30 a.m.
Break
 
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
 
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
 
12:10 to 1:10 p.m.
Lunch
 
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
 
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
 
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
 
3 to 3:20 p.m.
Break
 
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
 
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany

Registration

Registration

*Registration and lunches are limited to the first 350 registrants*
 
Research Overview
Research pioneered at City of Hope has improved the lives of men, women and children throughout the world.
 
Beckman Research Institute

Beckman Research Institute of City of Hope is internationally  recognized for its innovative translational biomedical research.
 

Comprehensive Cancer Center
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and education.

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Technology & Licensing
The Center for Applied Technology Development offers broad expertise in
technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

NEWS & UPDATES
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...
  • Cancer treatment can take a toll on the mouth, even if a patient’s cancer has nothing to do with the head or throat, leading to a dry mouth, or a very sore mouth, and making it difficult to swallow or eat. Here’s some advice from the National Cancer Institute (NCI)  on how to ease cancer-related dis...
  • Radiation oncology is one of the three main specialties involved in the successful treatment of cancer, along with surgical oncology and medical oncology. Experts in this field, known as radiation oncologists, advise patients as to whether radiation therapy will be useful for their cancer – and how it can best ...
  • There’s more to cancer care than simply helping patients survive. There’s more to cancer treatment than simple survival. Constant pain should not be part of conquering cancer,  insists Betty Ferrell, Ph.D., R.N., director of nursing research and education at City of Hope. She wants patients and caregivers...
  • Even its name is daunting. Systemic mastocytosis is a fatal disease of the blood with no known cure. But a new study suggests a bone marrow transplant may be the answer for some patients. While rare, systemic mastocytosis is resistant to treatment with drugs and, when aggressive, can be fatal within four years ...
  • Could what you eat affect the health of your chromosomes? The short answer is, “Yes.” Researchers led by Dustin Schones, Ph.D., assistant professor in the Department of Cancer Biology, and Rama Natarajan, Ph.D., director of the Division of Molecular Diabetes Research and the National Business Products Industry ...
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate health, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help yo...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...